May 23rd 2023
Diagnose, monitor, comanage—optometrists support patients throughout all stages of the disease.
April 22nd 2023
April 15th 2023
Pegcetacoplan approved by FDA for the treatment of geographic atrophyFebruary 17th 2023
Following the submission of the 24-month phase 3 data in November 2022, Apellis received FDA approval for intravitreal pegcetacoplan (SYFOVRE) to treat geographic atrophy secondary to AMD.
Apellis aims to submit 24-month Phase 3 data to FDA for pegcetacoplan NDANovember 4th 2022
The submission of 24-month efficacy data from DERBY and OAKS is classified as a Major Amendment to the New Drug Application, which delays the PDUFA target action date until February 2023.